Nektar Therapeutics Issues Equity Grants to New Hires

The Organization and Compensation Committee of the company’s board approved the issuance of 20,500 non-qualified stock options and 3,900 restricted stock units. These awards are tied to an exercise price of $60.98 per share, reflecting the closing market price on June 18, 2026. Under the terms of the plan, the options carry an eight-year term, while both the options and units feature a four-year vesting schedule contingent upon continued employment.

Nektar, which focuses on immunological treatments for autoimmune and chronic inflammatory diseases, established the 2025 Inducement Plan specifically to provide equity incentives to incoming staff. The program operates under Nasdaq Listing Rule 5635(c)(4), which allows for equity grants as a material inducement for new hires who were not previously affiliated with the organization.